Neogene Therapeutics to develop personalized cell therapies

By The Science Advisory Board staff writers

September 14, 2020 -- Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series A financing.

Neogene was founded in 2018 to advance the development of neoantigen T-cell therapies. Now, its proprietary platform allows for the isolation of neoantigen specific T-cell receptor (TCR) genes from tumor biopsies.

Tumor-infiltrating lymphocytes obtained from tumor biopsies express TCR specific for the mutated proteins found in cancer cells (neoantigens). Using DNA sequencing, DNA synthesis, and genetic screening tools, the company can identify neoantigen specific T-cell receptor genes that are subsequently engineered into personalized T cells to be used in T-cell therapies.

Initial seed funding in 2019 enabled Neogene to achieve proof of concept for its neoantigen technology platform. With the new financing, the company intends to further develop its technology with growing offices in Amsterdam and the U.S. with the goal to initiate phase I clinical studies in 2022.

New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that...
Atara advances CAR T technology with IND clearance
Atara Biotherapeutics said that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ATA2271, a...
Kite submits BLA for CAR T in non-Hodgkin lymphomas
Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel...
MD Anderson, Xencor partner on XmAb candidates
The University of Texas MD Anderson Cancer Center and Xencor have entered a strategic collaboration to study investigational treatments for cancers. Together,...
Unum Therapeutics transfers BOXR cell-based therapy to Sotio
Unum Therapeutics has sold its Bolt-on Chimeric Receptor (BOXR) cell-based therapy technology to immuno-oncology firm Sotio.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter